It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Travis C. Mickle net worth and biography

Travis Mickle Biography and Net Worth

CEO of Zevra Therapeutics

Dr. Mickle is a co-founder of KemPharm and has served as a member of our board of directors since our inception in 2006 and chairman of our board of directors from November 2014 to November 2021. Dr. Mickle served as our president and chief scientific officer from 2006 to October 2010, and has served as our president and chief executive officer since October 2010. Prior to founding KemPharm, Dr. Mickle spent five years with New River Pharmaceuticals, a specialty pharmaceutical company, where he was a senior research scientist from 2001 to 2002, the director of chemistry from 2002 to 2003 and the director of drug discovery and CMC from 2003 to 2005. Dr. Mickle received his Ph.D. degree from the University of Iowa and his B.A. degree from Simpson College.

What is Travis C. Mickle's net worth?: The estimated net worth of Travis C. Mickle is at least $0.00 as of May 25th, 2022. Dr. Mickle owns 39,521 shares of Zevra Therapeutics stock worth more than $0 as of April 25th. This net worth approximation does not reflect any other assets that Dr. Mickle may own. Learn More about Travis C. Mickle's net worth.
How do I contact Travis C. Mickle?: The corporate mailing address for Dr. Mickle and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Travis C. Mickle's contact information.
Has Travis C. Mickle been buying or selling shares of Zevra Therapeutics?: Travis C. Mickle has not been actively trading shares of Zevra Therapeutics over the course of the past ninety days. Most recently, on Wednesday, May 25th, Travis C. Mickle bought 3,000 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $4.37 per share, with a total value of $13,110.00. Following the completion of the transaction, the chief executive officer now directly owns 39,521 shares of the company's stock, valued at $172,706.77. Learn More on Travis C. Mickle's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes R. Clifton (CFO), Travis Mickle (CEO), Richard Pascoe (Chairman), and David Tierney (Director). Learn More on Zevra Therapeutics' active insiders.

Travis C. Mickle Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/25/2022	Buy	3,000	$4.37	$13,110.00	39,521
11/18/2021	Buy	2,250	$8.23	$18,517.50
8/30/2021	Buy	5,000	$8.92	$44,600.00	34,271
6/2/2020	Buy	110,000	$0.18	$19,800.00
3/5/2020	Buy	25,000	$0.31	$7,750.00
9/24/2019	Buy	50,000	$0.79	$39,500.00	1,713,117
10/12/2018	Buy	5,000	$2.55	$12,750.00	1,679,978
6/20/2017	Buy	8,000	$3.45	$27,600.00	1,629,612
3/22/2017	Buy	2,000	$4.10	$8,200.00	1,526,081
8/17/2016	Buy	5,000	$4.95	$24,750.00	1,381,176
3/29/2016	Buy	2,450	$14.57	$35,696.50	1,381,176

Travis C. Mickle Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Today's Range

Now: N/A

50 Day Range

MA: $5.51

$4.48

$6.27

2 Week Range

Now: N/A

Volume

64,100 shs

Average Volume

189,500 shs

Market Capitalization

$200.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.16

Will this $2 AI stock double overnight?

From Behind the Markets | Ad